173 related articles for article (PubMed ID: 29335872)
1. Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches.
Sabatino M; Rotili D; Patsilinakos A; Forgione M; Tomaselli D; Alby F; Arimondo PB; Mai A; Ragno R
J Comput Aided Mol Des; 2018 Mar; 32(3):435-458. PubMed ID: 29335872
[TBL] [Abstract][Full Text] [Related]
2. Nucleoside and Non-Nucleoside DOT1L Inhibitors: Dawn of MLLrearranged Leukemia.
Cao M; Li T; Chen Y; Zhai X
Mini Rev Med Chem; 2021; 21(11):1337-1350. PubMed ID: 33430727
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.
Song Y; Li L; Chen Y; Liu J; Xiao S; Lian F; Zhang N; Ding H; Zhang Y; Chen K; Jiang H; Zhang C; Liu YC; Chen S; Luo C
Bioorg Med Chem; 2018 May; 26(8):1751-1758. PubMed ID: 29534934
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (SAM)-Dependent Methyltransferase Family.
Wang Y; Li L; Zhang B; Xing J; Chen S; Wan W; Song Y; Jiang H; Jiang H; Luo C; Zheng M
J Med Chem; 2017 Mar; 60(5):2026-2036. PubMed ID: 28165739
[TBL] [Abstract][Full Text] [Related]
5. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
6. Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.
Gibbons GS; Chakraborty A; Grigsby SM; Umeano AC; Liao C; Moukha-Chafiq O; Pathak V; Mathew B; Lee YT; Dou Y; Schürer SC; Reynolds RC; Snowden TS; Nikolovska-Coleska Z
Eur J Med Chem; 2020 Mar; 189():112023. PubMed ID: 31978781
[TBL] [Abstract][Full Text] [Related]
7. Identification of Novel Disruptor of Telomeric Silencing 1-like (DOT1L) Inhibitors through Structure-Based Virtual Screening and Biological Assays.
Chen S; Li L; Chen Y; Hu J; Liu J; Liu YC; Liu R; Zhang Y; Meng F; Zhu K; Lu J; Zheng M; Chen K; Zhang J; Jiang H; Yao Z; Luo C
J Chem Inf Model; 2016 Mar; 56(3):527-34. PubMed ID: 26914852
[TBL] [Abstract][Full Text] [Related]
8. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L.
Basavapathruni A; Jin L; Daigle SR; Majer CR; Therkelsen CA; Wigle TJ; Kuntz KW; Chesworth R; Pollock RM; Scott MP; Moyer MP; Richon VM; Copeland RA; Olhava EJ
Chem Biol Drug Des; 2012 Dec; 80(6):971-80. PubMed ID: 22978415
[TBL] [Abstract][Full Text] [Related]
9. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Lillico R; Lawrence CK; Lakowski TM
J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
[TBL] [Abstract][Full Text] [Related]
10. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
Chen CW; Armstrong SA
Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
[TBL] [Abstract][Full Text] [Related]
11. Computer-Aided Discovery of Massonianoside B as a Novel Selective DOT1L Inhibitor.
Chen J; Park HJ
ACS Chem Biol; 2019 May; 14(5):873-881. PubMed ID: 30951287
[TBL] [Abstract][Full Text] [Related]
12. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
Anglin JL; Song Y
J Med Chem; 2013 Nov; 56(22):8972-83. PubMed ID: 23879463
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L.
Anglin JL; Deng L; Yao Y; Cai G; Liu Z; Jiang H; Cheng G; Chen P; Dong S; Song Y
J Med Chem; 2012 Sep; 55(18):8066-74. PubMed ID: 22924785
[TBL] [Abstract][Full Text] [Related]
14. Novel DOT1L ReceptorNatural Inhibitors Involved in Mixed Lineage Leukemia: a Virtual Screening, Molecular Docking and Dynamics Simulation Study.
Raj U; Kumar H; Gupta S; Varadwaj PK
Asian Pac J Cancer Prev; 2015; 16(9):3817-25. PubMed ID: 25987043
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and anti leukemia cells proliferation activities of pyrimidylaminoquinoline derivatives as DOT1L inhibitors.
Zhang L; Chen Y; Liu N; Li L; Xiao S; Li X; Chen K; Luo C; Chen S; Chen H
Bioorg Chem; 2018 Oct; 80():649-654. PubMed ID: 30059890
[TBL] [Abstract][Full Text] [Related]
16. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
Kari V; Raul SK; Henck JM; Kitz J; Kramer F; Kosinsky RL; Übelmesser N; Mansour WY; Eggert J; Spitzner M; Najafova Z; Bastians H; Grade M; Gaedcke J; Wegwitz F; Johnsen SA
Clin Epigenetics; 2019 Jan; 11(1):4. PubMed ID: 30616689
[TBL] [Abstract][Full Text] [Related]
17. Structure-guided DOT1L probe optimization by label-free ligand displacement.
Yi JS; Federation AJ; Qi J; Dhe-Paganon S; Hadler M; Xu X; St Pierre R; Varca AC; Wu L; Marineau JJ; Smith WB; Souza A; Chory EJ; Armstrong SA; Bradner JE
ACS Chem Biol; 2015 Mar; 10(3):667-74. PubMed ID: 25397901
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies.
Yao Y; Chen P; Diao J; Cheng G; Deng L; Anglin JL; Prasad BV; Song Y
J Am Chem Soc; 2011 Oct; 133(42):16746-9. PubMed ID: 21936531
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
Zhang X; Liu D; Li M; Cao C; Wan D; Xi B; Li W; Tan J; Wang J; Wu Z; Ma D; Gao Q
J Hematol Oncol; 2017 Jan; 10(1):29. PubMed ID: 28114995
[TBL] [Abstract][Full Text] [Related]
20. Computational modeling reveals key molecular properties and dynamic behavior of disruptor of telomeric silencing 1-like (DOT1L) and partnering complexes involved in leukemogenesis.
Stodola TJ; Chi YI; De Assuncao TM; Leverence EN; Tripathi S; Dsouza NR; Mathison AJ; Volkman BF; Smith BC; Lomberk G; Zimmermann MT; Urrutia R
Proteins; 2022 Jan; 90(1):282-298. PubMed ID: 34414607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]